Clinical trial · Interventional
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer
NCT02739204CI-TRIAL-00021769unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The research and development of novel anti-tumor agents in oral cancer is slow, the investigation of repositioning use of currently available drugs in clinical, such as a selective cyclooxygenase-2 (COX-2) inhibitor (Celebrex/Celecoxib) maybe a potential alternative strategy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Celecoxib | Drug | Celecoxib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Celecoxib
- description
- Combination of concurrent radiotherapy and/or Cisplatin with or without Celcoxib
- interventionNames
- Drug: Celecoxib
Primary outcomes (1)
- measure
- Relapse-free recurrence
- timeFrame
- 3 year relapse-free recurrence
- description
- 3-year follow-up after 6-month treatment of Celecoxib
Secondary outcomes (1)
- measure
- Relapse-free survival
- timeFrame
- 3 year relapse-free survival
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. OSCC patients with T1,2/ N0 and without pathological risk features 2. OSCC patients with T1,2/ N0,1 and pathological risk features 3. OSCC patients with T4a/ N2,3 Exclusion Criteria: 1. Pregnant women paitents 2. Taiwanese aboriginal patients 3. Not primary OSCC patients 4. OSCC patients with dysfunction of liver and/or kidneys
References
Publications (0)
Data not yet available
No reference posted for this study.